How does ocrelizumab act on CD20-expressing B cells?

The answer

Answer

Ocrelizumab selectively binds to and depletes CD20-expressing B cells through antibody-dependent cellular phagocytosis, antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and apoptosis; its precise therapeutic mechanism in multiple sclerosis is not fully understood.

Sources for this answer

OCREVUS 300 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 22Document updated 29 September 2026

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

Answer

Sources for this answer

More questions about ocrelizumab

Answer

Sources for this answer

More questions about ocrelizumab

ocrelizumab

More clinical questions?